Accepted Manuscript

Inhibition of Myeloperoxidase: Evaluation of 2H-Indazoles and 1H-Indazolones

Aaron Roth, Sean Ott, Kelli M. Farber, Teresa A. Palazzo, Wayne E. Conrad, Makhluf J. Haddadin, Dean J. Tantillo, Carroll E. Cross, Jason P. Eiserich, Mark J. Kurth

PII: DOI: Reference:	S0968-0896(14)00698-1 http://dx.doi.org/10.1016/j.bmc.2014.09.044 BMC 11831
To appear in:	Bioorganic & Medicinal Chemistry
Received Date:	17 July 2014
Revised Date:	13 September 2014
Accepted Date:	20 September 2014



Please cite this article as: Roth, A., Ott, S., Farber, K.M., Palazzo, T.A., Conrad, W.E., Haddadin, M.J., Tantillo, D.J., Cross, C.E., Eiserich, J.P., Kurth, M.J., Inhibition of Myeloperoxidase: Evaluation of 2*H*-Indazoles and 1*H*-Indazolones, *Bioorganic & Medicinal Chemistry* (2014), doi: http://dx.doi.org/10.1016/j.bmc.2014.09.044

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.

?

R

Inhibition of Myeloperoxidase: Evaluation of 2*H*-Indazoles and 1*H*-Indazolones

Leave this area blank for abstract info.

Aaron Roth^{*a*}, Sean Ott^{*b*}, Kelli M. Farber^{*a*}, Teresa A. Palazzo^{*a*}, Wayne E. Conrad^{*a*}, Makhluf J. Haddadin^{*c*}, Dean J. Tantillo^{*a*}, Carroll E. Cross^{*b*}, Jason P. Eiserich^{*b*}, and Mark J. Kurth^{*a*} Department of Chemistry^{*a*} & Department of Internal Medicine^{*b*}, University of California, Davis Department of Chemistry^{*c*}, American University of Beirut, Beirut, Lebanon



Bioorganic & Medicinal Chemistry

Inhibition of Myeloperoxidase: Evaluation of 2*H*-Indazoles and 1*H*-Indazolones

Aaron Roth^{*a*}, Sean Ott^{*b*}, Kelli M. Farber^{*a*}, Teresa A. Palazzo^{*a*}, Wayne E. Conrad^{*a*}, Makhluf J. Haddadin^{*c*}, Dean J. Tantillo^{*a*}, Carroll E. Cross^{*b*}, Jason P. Eiserich^{*b*}, and Mark J. Kurth^{*a*,*}

^aDepartment of Chemistry, University of California, One Shields Avenue, Davis, California 95616

^bDepartment of Internal Medicine, Division of Pulmonary/Critical Care Medicine, 4150 V Street, Suite 3100, Sacramento, CA 95817

^cDepartment of Chemistry, American University of Beirut, Beirut, Lebanon

ARTICLE INFO

ABSTRACT

Article history: Received Received in revised form Accepted Available online

Keywords: Myeloperoxidase Davis-Beirut reaction 2*H*-indazole Structure-activity relationship Computational docking Myeloperoxidase (MPO) produces hypohalous acids as a key component of the innate immune response; however, release of these acids extracellularly results in inflammatory cell and tissue damage. The two-step, one-pot Davis-Beirut reaction was used to synthesize a library of 2*H*-indazoles and 1*H*-indazolones as putative inhibitors of MPO. A structure-activity relationship study was undertaken wherein compounds were evaluated utilizing taurine-chloramine and MPO-mediated H₂O₂ consumption assays. Docking studies as well as toxicophore and Lipinski analyses were performed. Fourteen compounds were found to be potent inhibitors with IC₅₀ values <1 μ M, suggesting these compounds could be considered as potential modulators of prooxidative tissue injury pertubated by the inflammatory MPO:H₂O₂:HOCl/ HOBr system.

2009 Elsevier Ltd. All rights reserved.

1. Introduction

Myeloperoxidase (MPO), primarily found in azurophilic granules of polymorphonuclear neutrophils (PMNs), is a key component of the innate immune response.¹⁻⁵ Specifically, MPO acts as an important antimicrobial effector through its enzymatic production of hypohalous acids (e.g. HOCl, HOBr). These acids promote phagosomal oxidative antimicrobicidal activities, but if secreted or released extracellularly, can present a potent instigator of cell and tissue damage in the inflammatory milieu.² Active MPO has been found in or associated with a variety of disorders including atherosclerosis, Alzheimer's disease, neutrophil mediated glomerular injury, and idiopathic pulmonary fibrosis.²

Mediation of the effects of MPO related oxidative stress in patients with cystic fibrosis is a particularly pressing challenge. Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in a single gene encoding the glycoprotein CF transmembrane conductance regulator (CFTR). Loss of CFTR function in respiratory tract (RT) tissues results in a thickened, under-hydrated RT mucus secretion. This in turn leads to reduced mucociliary airway clearance, airway bacterial colonization, infection, and an overly exuberant dysregulated RT inflammatory response characterized by an intense airway neutrophil influx.⁶ Overactive recruited neutrophil effector proteolytic and oxidative processes are believed to represent the most debilitating feature of CF leading to progressively more severe RT disease and eventual RT failure, which characterizes end stage CF.⁶⁷

*Corresponding author. Tel.: 530-554-2145; fax: 530-752-8995. E-mail address: <u>mjkurth@ucdavis.edu</u> (M. J. Kurth) Neutrophil-derived MPO, known to represent the strongest and most abundant oxidative effector system in neutrophils, is present in CF RT fluids in early stages of the disease⁸ and in increasingly large quantities in later stages of the disease.⁹ Indeed, both circulating and RT MPO levels have been found to correlate with disease severity in CF.^{7,10,11} MPO's extracellular releases are suspected to play an important role in the pathophysiology of numerous other inflammatory diseases including both RT and cardiovascular diseases through its (i) direct oxidation and (ii) production of hypohalous acids.^{5,12-16}

In CF patients with advanced RT disease, opportunities exist for the development of small molecules to target the major molecular components of the neutrophil proteolytic and oxidative related mediators of RT pathobiology.^{12,13} One such pathway is represented by MPO. Despite its high expression in CF RT disease,^{9,14} implications that MPO polymorphisms leading to greater levels of MPO expression are associated with more severe RT CF diseases,^{13,17} and recognition as a viable drug target¹⁸ with animal experimental evidence,¹⁹ we know of no studies to date that have directly addressed the effects of inhibition or absence of MPO in CF RT pathobiology. This is the case even though several promising recent experimental approaches have been designed to therapeutically target prooxidative MPO activities.^{20,21}

The structural similarity of 2*H*-indazoles to previously reported inhibitors, such as indoles and hydroxamic acids, inspired our exploration of their inhibitory activity. Furthermore, we hypothesized that 2*H*-indazoles and 1*H*-indazolones would have greater bioavailability due to the second polar nitrogen in

the core scaffold. Specifically, we sought to examine chain length tolerance at the synthetically accessible N^1 , N^2 , and C^3 positions as wells as the effect of polar, non-polar and aromatic substituents. Since terminal polar substituents on long alkyl chains have been shown to be a beneficial structural motif in previous MPO inhibitors,²² a subset of this initial library containing this feature was synthesized in hopes of replicating these previous successes. Herein, we describe the synthesis, computational analysis, structure-activity relationship (SAR) insights, and evaluation of 2*H*-indazoles and 1*H*-indazolones as inhibitors of MPO.

2. Results and Discussion

2.1 Chemistry

The 3-alkoxy-2*H*-indazoles employed in this study were prepared by the versatile Davis-Beirut reaction $(DBR)^{23-29}$ on 2-nitrobenzylamine **3**, in turn prepared by one of two complimentary methods: (i) commercially available 2-nitrobenzyl bromide (1) was used to *N*-alkylate the requisite amine to form intermediate **3** (Scheme 1/Method A) or (ii) **3** was prepared by reductive amination of the requisite 2-nitrobenzaldehyde (Scheme 1/Method B). Regardless of the route to **3**, this 2-nitrobenzylamine intermediate need not be isolated. Rather, the DBR is initiated by direct addition of alcoholic potassium hydroxide to the Method A or Method B reaction mixture containing **3**, which leads to the targeted 3-alkoxy-2*H*-indazole **4** in good to excellent overall yield (49–87% for this two-step, one-pot process).

Likewise, the 1*H*-indazolones (**5** and **6**; Scheme 1) employed in this study were prepared through one of two complimentary methods from the DBR-derived 3-alkoxy-2*H*-indazole **4**. In the first method (C), 3-alkoxy-2*H*-indazole **4** was heated to 100 °C in 0.3 M methanolic H₂SO₄ to affect a proto-dealkylation (e.g., loss of \mathbb{R}^2) reaction to deliver the targeted N^1 -unsubstituted 1*H*indazolone **5** (52 – 94% yield). In the second method (D), N^1 substituted 1*H*-indazolone **6** was obtained by an electrophilemediated domino N^1 -alkylation/*O*-dealkylation process, which provides the targeted heterocycle in excellent yield (70-95%).



Scheme 1. Reagents and conditions: (a) H_2NR^1 , DIPEA, R^2OH (solvent); (b) H_2NR^1 , AcOH, R^2OH (solvent) then NaCNBH₃; (c) KOH in 10% H_2O (v/v), 65°C; (d) 0.3 M methanolic H_2SO_4 /sealed vial, 100 °C; (e) R^3X , CH₃CN, reflux.

Finally, the R¹-constrained 2*H*-indazole analogs – i.e., containing $N^2 - C^3$ fused ring systems – employed in this study (see $9 \Rightarrow 7$ and $12 \Rightarrow 11$; Scheme 2) were obtained by intramolecular nucleophilic attack onto the corresponding DBR nitroso-imine intermediate (cf., $8 \rightarrow 9$). Conventionally, hydroxyl has been the internal nucleophile utilized in R¹-constrained DBRs, which provides access to oxazolino- (9; n = 1) and oxazino-2*H*-indazoles (9; n = 2; Scheme 2). However, recent advances have expanded the scope of the R¹-constrained DBR to include thiol as the internal nucleophile.³⁰ In this modification, *N*-(2-nitrobenzyl)-2-(trityl-thio)alkylamine 10, formed from 2 via Method B, is trityl deprotected with TFA to give thiol 11, which is then subjected to R¹-constrained DBR conditions to deliver the thiazolino- (12a, b; n = 1) and thiazino-2*H*-indazoles (12b, c; n = 2) in 66 – 83% yield.



Scheme 2. Reagents and conditions: (a) $H_2N(CH_2)_nOH$, DIPEA, *i*PrOH; (b) $H_2N(CH_2)_nOH$ (\rightarrow 9) or $H_2N(CH_2)_nSTr$ (\rightarrow 10), DIPEA, *i*PrOH; then NaCNBH₃; (c) KOH in 10% H_2O (v/v), 65°C; (d) TFA, TES, DCM, 1 h, r.t.

2.2 Molecular Docking

Computational docking, performed using *FRED* (OpenEye software suite),³¹⁻³³ was utilized to help characterize interactions within the active site. Docking study validation was accomplish-



Figure 1. Structural layover of naturally bound HX1 (green) and docked HX1 (grey) indicating an effective docking model (RMSD = 1.2 Å).

ed through comparative docking of the 5-fluoroindole scaffold described by Soubhye,²² and HX1²⁰ bound in the active site of MPO [Figure 1; (PDB ID 4C1M), RMSD docked vs. natural is 1.2 Å]. Also included in the docking studies was 4-aminobenzoic acid hydrazide, the internal control for the assays discussed herein, which consistently displayed an IC₅₀ of 81 +/- 19 nM.



Figure 2. Compound 4a docked into the active site of MPO (crystal structure obtained from PDB ID 4C1M).

These docking studies indicated that the 2*H*-indazoles, like previously reported inhibitors, likely sit in a stacked fashion over the heme lending credence to our inhibitor design approach. For example, compound **4a** (Figure 2) is positioned in such a way that the alkyl chain on the N^2 -position extends out toward the hydrophobic pocket, while the aromatic core scaffold stacks over the pyrrole rings of the heme porphyrin. **2.3 Structure-Activity relationship**

4-Aminobenzoic acid hydrazide was used as an internal control while MPO inhibitory activity was assessed using a taurine-chloramine assay to measure enzymatic hypochlorous acid production. Select IC₅₀ values were confirmed utilizing a H₂O₂-specific electrode allowing for real time hydrogen peroxide concentration measurements (Supporting Information). Upon generation of an initial library of 2H-indazoles (Table 1), a consistent trend was found wherein, as the length of the chain increased, there was a dramatic decrease in inhibitory potency. For example, increasing the length of the chain from four (4f) to five (4g) carbons resulted in a three-fold decrease in potency. Compound 41 was included to ensure that this decrease in efficacy was not a result of reduced solubility. The compounds synthesized containing terminal polar substituents (4j - 4l, Table 1) failed to elicit a significant increase in inhibitory activity. It is possible that these modifications were not effective due to a change in orientation of the inhibitor with respect to the indole scaffold or because the alcohol moiety failed to carry a positive charge necessary to lower binding energy. A series of N^2 -aryl analogues (4m - 4q) was included to explore the effects of more rigid, hydrophobic substituents that likely extend into the pocket of the MPO active site, but these compounds failed to produce an appreciable increase in inhibitor activity.

Lastly, by lengthening the alkoxy substituent at C^3 , we also sought to probe the relationship between substituents on the 3position of both scaffolds [e.g.; **4a** -OMe \rightarrow **4b** -OEt \rightarrow **4c** -O-(CH₂)₂OMe]. With this SAR study, we noted decreased inhibition of MPO as the length of the alkoxy chain was extended past two carbons. This trend is likely the result of increased inhibitor size within the relatively small distal portion of the active site.

As before, docking studies of the synthesized inhibitors indicate that the aromatic portion of the inhibitors is positioned in a π -stacking fashion over pyrrole ring D of the heme, while the hydrophobic portion extends into the cavernous hydrophobic pocket. If hydrogen bond donors are present, they are generally oriented toward the carboxylate groups of the heme. Because the same orientation was maintained, it followed that increasing steric bulk at the C^3 -position would decrease inhibitor activity due to the constraints of the active site. Interestingly, docking



Table 1. IC₅₀ values of 3-alkoxy-2*H*-indazoles assessed with a Taurine chlorination assay (154 mM NaCl, 30 μ M H₂O₂, and 2 nM MPO). All IC₅₀ values are expressed in nM as a mean of \geq 3 trials +/- standard deviation.



Table 2: IC₅₀ values of 1*H*-indazolones assessed with a Taurine chlorination assay (154 mM NaCl, 30 μ M H₂O₂, and 2 nM MPO). All IC₅₀ values are expressed in nM as a mean of \geq 3 trials +/- standard deviation.

studies indicated that incorporation of the benzodioxole ring (4a \rightarrow 4d) changes the inhibitor orientation in the active site. Here, rather than the aromatic core of the inhibitor occupying the space directly above the iron, the inhibitor is shifted such that the benzodioxole ring is positioned above the heme iron center.



Figure 3. Compound 4d in the MPO active site. The benzodioxole moitey now resides over the heme center while the tethered ring extends into the hydrophobic pocket.

Owing to the presence of a basic nitrogen in the core scaffold and mildly acidic assay conditions, a portion of the inhibitor is expected to exist in the protonated form. Therefore, a protonated species of each molecule was docked for comparison. It was found that, in some cases, protonation created the opportunity for additional hydrogen bond and charge-charge interactions with the carboxylate groups of the heme. It should be noted that, in this instance, a direct correlation between IC₅₀ values and docking scores could not generally be obtained through the use of conventional docking programs.³⁴

Interestingly, conversion of 3-alkoxy-2*H*-indazoles to the corresponding N^l -substituted 1*H*-indazolones resulted in significantly decreased inhibitory activity while the unsubstituted 1*H*-indazolones retained inhibitory potency (Table 2). Docking studies indicate that if N^l -substituted 1*H*-indazolones were to enter the active site, they would likely adopt a pose similar to the

 N^1 -unsubstituted 1*H*-indazolones. We hypothesize that substituents at the N^I -position results in the loss of a crucial interaction with either the carboxylate groups of the heme or the glutamate anion within the active site.³⁵ These observations are consistent with the findings of Sliskovic³⁵ wherein *N*-alkylation of the indole scaffold resulted in reduced inhibitor potency. Based on these SAR results, it is clear that either the accessible lone pair or nucleophilic nitrogen is essential for inhibitory activity.³⁵

When studying the 5-fluoroindole scaffold, Soubhye²² found that compounds with longer alkyl chains in the 3-position displayed better inhibitory efficacy than their "less greasy" counterparts. In the case of these indazolo analogues, it is interesting to note that increasing the length of the alkyl chain of N^2 or C^3 was only beneficial to a certain point. For example, a branched alkyl chain (isopropyl; **4a**) was well tolerated, while an *n*-pentyl (**4g**) or *n*-octyl chain (**4h**) decreased inhibitory activity. It is important to note that increasing the length of an alkyl chain cause issues with solubility or with the molecule's ability to enter the active site, even if it may be beneficial within the active site.

We next set out to explore the use of constrained analogues of the 2*H*-indazole scaffold – i.e., containing $N^2 - C^3$ fused ring systems - in hopes that this would facilitate passage through the narrow pore to the exposed heme. A series of both substituted and unsubstituted oxazolino- and oxazinoindazoles were synthesized. Also, taking advantage of newly developed methodology to access substituted and unsubstituted thiazolinoand thiazino-2H-indazoles,³⁰ we were able to explore variation of the heteroatom substituent at the C^3 -position. Indeed, it was found that both ring size and the nature of the heteroatom are determining factors in inhibitory potency. Constraining the N^2 position resulted in significantly increased inhibitory activity by possibly facilitating entrance into the active site (Table 3). Furthermore, by changing from an oxygen substituent (9c) to a sulfur substituent (12c) in the tethering ring, a 40% improvement in potency was observed. Additional improvement (56%) was observed when the tethering ring size was reduced from six-(12c) to five-membered [12a; note that the O-analog of 12a (i.e., "S" replaced with "O"), unlike substituted versions 9a and 9b, is



Table 3. IC₅₀ values of constrained 2*H*-indazole analogues assessed with a Taurine chlorination assay (154 mM NaCl, 30 μ M H₂O₂, and 2 nM MPO). All IC₅₀ vales are expressed in nM as a mean of \geq 3 trials +/- standard deviation.

unstable²³]. Seeking to build upon these successes, we set out to incorporate the benzodioxole moiety into the S-constrained scaffold (i.e., $12a \rightarrow 12b$), which docking studies suggest causes a change in the orientation of the inhibitor in the active site (see Supporting Information/12b/pg S25). To our delight, incorporation of the 1,3-benzodioxole ring provided markedly improved inhibitory activity (see 12b and 12d; Table 3) and we speculate that addition of the benzodioxole ring reduces the likelihood of electrophilic attack and/or MPO compound I mediated oxidation.³⁶ To confirm that the observed active inhibitors 12a-d are the unoxidized thiazino- or thiazolino-systems, rather than the corresponding sulfoxides and/or sulfones, inhibitors 12a-d were treated with excess NaOCl and examined by liquid chromatography/mass spectrometry (LC/MS) at 1 h and 24 h. Only trace sulfoxide formation was detected at 24 h (detectable by MS, but not diode array).

oun	\$		0	4	ecular	cking	M
Comp	HBD	HBA	+1.0g1	2085	Monveils	Dogcol	1050
12b	0	3	1.72	36.28	220.3	-44.74	87
12a	0	1	1.99	17.82	176.2	-46.65	94
12d	0	3	2.21	36.28	234.3	-41.23	140
12c	0	1	2.48	17.82	190.3	-43.61	213
9c	0	2	1.75	27.05	174.2	-38.09	359
9e	0	4	1.48	45.51	218.2	-35.45	403
5a	1	2	2.03	37.79	176.2	-39.94	660
4a	0	2	2.76	27.05	190.2	-47.20	704
4d	0	4	2.49	45.51	234.3	-63.55	711
4b	0	2	3.16	27.05	204.3	-50.03	722
5b	1	2	2.48	37.79	190.2	-48.13	792
4f	0	2	3.61	27.05	218.3	-53.95	807
9a	~ 0	2	1.79	27.05	174.2	-39.72	900
4e	0	2	3.21	27.05	204.3	-50.64	910

Table 4. Drug like properties of select compounds (mean IC_{50} values are shown); see *Supporting Information* for a complete tabulation of results.

Further computational analysis was undertaken to examine the drug-like properties for both classes of inhibitors using OpenEye software. As detailed in Table 4, the parameters examined included the presence of hydrogen bond donors (HBD) and hydrogen bond acceptors (HBA), LogP, 2D Polar Surface Area (PSA), and the potential for aggregation. It was found that, of the fourteen compounds which demonstrate potencies less than 1

µM, those containing less than two HBD and HBA's scored better with our docking methods. It is interesting to note that even with relatively few HBD and HBA's, active 2H-indazoles and 1H-indazolones still maintain satisfactory calculated LogP vales. For example, compound 12b was calculated to have a LogP of 1.72, while the protonated form of 4e, containing a comparatively greasy butyl substituent, has a calculated LogP of 3.94. In addition, Veber and Kopple found an increased probability of satisfactory oral bioavalibility through passive diffusion existed if compounds contained a PSA of less than 140 Å^2 and fewer than ten rotatable bonds.³⁷ Additionally, Hou and Xu found that reduced polar surface area and molecular weight below 350 Daltons facilitates passage through the blood brain barrier.38 Efficient passage through this barrier could prove essential in the treatment of diseases such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease through inhibition of MPO.^{2,39} Furthermore, it was found that all 2H-indazoles and 1H-indazolones were unlikely to act as aggregators based on a structure based screen. This analysis underwrites the further consideration of the potential efficacy of these compounds as drugs. A complete tabulation of this analysis is available in the Supporting Information.

3. Conclusion

A series of 2H-indazoles and 1H-indazolones were synthesized utilizing the Davis-Beirut reaction, and evaluated as potential MPO inhibitors. Fourteen of these compounds displayed potent IC₅₀ values (nanomolar range) as assessed utilizing taurine-chloramine inhibition and H₂O₂ consumption assays. Compounds containing N^1 -substituents were not effective inhibitors, while compounds with relatively small substituents at N^2 and C^3 were most active. The most potent compounds in the series were constrained 2H-indazole analogues - i.e., containing $N^2 - C^3$ fused ring systems – with the most potent also incorporating a 1,3-benzodioxole ring. The present data suggests that, like the 2-thioxanthines,²¹ the recently described modified hydroxamates,²⁰ the tetramethyl and tetraethyl nitroxides ⁴⁰ and targeted MPO-modulating oligopeptide,⁴¹ 2H-indazoles and 1Hindazolones should be considered for possible therapeutic inhibition of unwarranted MPO activity in inflammatory diseases characterized by episodes of heightened neutrophil activation and convincing evidences of MPO-related pro-oxidative tissue injury. Such investigations will need to take into consideration toxicology and pharmacokinetic activities in complex biological fluids such as plasma, joint fluids, respiratory tract mucus secretions, and in complex inflammatory milieu.

4. Experimental

4.1 Docking protocols

All docking was performed using the OpenEye Suite of programs.³¹⁻³³ A receptor to model the MPO active site was set up using the Protein Data Bank (PDB) file $4C1M^{20}$ utilizing the *FRED* receptor program. The series of molecules studied herein were built using *Gaussview 5.0.9* associated with *Gaussian09*⁴² and saved as a library (.oeb.gz). The 5-fluoroindole with inhibitory activity previously published by Soubhye²² was included in this library to ensure that our docking methods were sound. All small molecules in the library were subject to a conformational search using *Omega2*. The conformers of each small molecule were then docked into the active site using *FRED*. Chemgauss3 scoring was employed.

4.2 Taurine chlorination assay

Taurine chloramine was measured using a modified method from Dypbukt et al.⁴³ In a volume of 125 μ L, the final reaction mixture contained 6.8 mM taurine, 2nM MPO, 105 mM NaCl, and various inhibitor concentrations in 20 mM phosphate buffer, pH 6.5. The reaction was initiated with 40 μ M H₂O₂, and after 5 min. was terminated with the addition of 4 ug catalase. To determine the amount of taurine chloramine produced, an equal volume of color developing solution containing 500 uM 3,3',5,5'-Tetramethylbenzidine and 100 μ M sodium iodide in 300 mM acetate buffer, pH 5.4. Absorbance was measured in a spectrophotometric microplate reader (PowerWave; Biotek Instruments Inc.) at a wavelength of 650 nm.

4.3 H₂O₂ mediated MPO inhibition assay

 H_2O_2 was measured using a H_2O_2 -specific electrode (World Precision Instruments, Sarasota, FL). The electrode was submerged in a continuously stirred reaction vessel containing 30 μ M H_2O_2 , 154 mM NaCl, and various inhibitor concentrations in 10 mM phosphate buffer, pH 7.4. The reaction was initiated with the addition of 10 nM MPO. Data was collected using a free radical analyzer (World Precision Instruments, Sarasota, FL) and a PowerLab data acquisition system (ADInstruments, Colorado Springs, CO).

4.4 Chemistry

All solvents and reagents were purchased from commercial suppliers and used without further purification. For reactions run in sealed microwave vials, oven-dried Biotage® 5-10 mL or 10-20 mL vials containing a Teflon-coated stirrer bar and sealed with a Teflon-lined septum were used. Analytical thin layer chromatography was carried out on pre-coated plates (Silica gel 60 F254, 250 μ m thickness) and visualized with UV light. Flash chromatography was performed with 60 Å, 35-70 μ M silica gel (Acros Organics). Concentration refers to rotary evaporation under reduced pressure.

¹H NMR spectra were recorded on Varian spectrometers operating at 600 MHz at ambient temperature with CDCl₃ or DMSO- d_6 as solvent. ¹³C NMR spectra were recorded on Varian spectrometers operating at 150 MHz at ambient temperature with CDCl₃ or DMSO- d_6 as solvent. Data for ¹H NMR are recorded as follows: chemical shift (δ , ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; m, multiplet; br, broad; app, apparent), integration, coupling constant (Hz). Chemical shifts are reported in parts per million relative to CDCl₃ (¹H, δ 7.26, ¹³C, δ 77.16), DMSO (¹H, δ 2.50, ¹³C, δ 39.5) or TMS (¹H, δ 0.00, ¹³C, δ 0.00). Infrared spectra were recorded on an ATI-FTIR spectrometer. The specifications of the LC/MS are as follows: electrospray (+) ionization, mass range 150-1500 Da, 20 V cone voltage, and Xterra MS C18 column (2.1 mm x 50 mm x 3.5 μ m).

4.4.1 General procedure for synthesis of 3alkoxy-2*H*-indazoles – Method A (4a-4l)

2-Nitrobenzyl bromide (15.31 mmol) was dissolved in alcoholic solvent (typically MeOH or EtOH, 115 mL) and added dropwise to a stirring solution of requisite primary amine (61.2 mmol), DIPEA (61.2 mmol), and 38 mL of alcoholic solvent over 6 h and then left stirring overnight. Water (15 mL) and KOH (76.6 mmol) were then added and this mixture was heated at 60 °C for 24 h and monitored by thin layer chromatography. When the starting material had been consumed, 50 mL of water was added and the alcoholic solvent was removed under reduced pressure. This aqueous mixture was then extracted twice with dichloromethane. The combined organic extracts were washed with water and brine, dried over sodium sulfate, and concentrated. The crude mixture was purified by flash chromatography to afford the title compound.²³

4.4.2 General procedure for preparation of 3-alkoxy-2*H*-Indazoles – Method B (4m-4p)

2-Nitrobenzaldehyde (5.22 mmol) and the requisite amine (6.26 mmol) were dissolved in alcoholic solvent (typically MeOH or EtOH, 13 mL) in a 250 mL round bottom flask. Glacial acetic acid (26.1 mmol) and sodium cyanoborohydride (6.26 mmol) were added and this solution was stirred at room temperature for 2.5 h. Additional alcoholic solvent (37 mL) and a solution of KOH (78.3 mmol) in water (6 mL) were added, a water-cooled reflux condenser was attached and this solution was heated at reflux for 2 h. The reaction mixture was then cooled to room temperature, water (20 mL) was added, and the alcoholic solvent was removed by rotary evaporation. This aqueous mixture was then neutralized with 1N HCl and extracted with ethyl acetate (3 X 30 mL). The combined organic extracts were then washed with 1N HCl (40 mL), saturated sodium carbonate (40 mL), water (40 mL), and brine (40 mL), dried over anhydrous sodium sulfate, and concentrated and purified by flash chromatography to afford the title compound.²⁴

4.4.3 Synthesis of 2-(4-ethynylphenyl)-3-methoxy-2*H*-indazole (4q)

Compound 40 (10.05 mmol) was added to a flame dried 250 mL round bottomed flask and dissolved in dry Tetrahydrofuran (16 mL) under Nitrogen gas. PdCl₂(PPh₃)₂ (0.50 mmol), CuI (1.00 mmol), and triethylamine (16 mL) were added and the reaction mixture cooled to 0 °C. Trimethylsilylacetylene (15.10 mmol) was added dropwise, then the reaction allowed to stir at room temperature. Formation of the protected silvl intermediate was complete after 1 h and 20 min. as shown by TLC. Approximately 5 g of sodium carbonate was added to the reaction and allowed to stir for 12 h to effect removal of silvl protecting group. Water (10 mL) was added to the reaction and the reaction mixture was extracted with ethyl acetate (3 x 30 mL). The organic extracts were combined, washed with brine, dried over anhydrous sodium sulfate, and purified by flash chromatography (10% ethyl acetate/hexanes) to afford 4q (1.952 g, 78% yield) as an off-white solid.

4.4.4 General procedures for the synthesis of substituted [1,3]oxazino[3,2-b]indazoles and 2,3-dihydrooxazolo[3,2-b]indazoles (9a-9d)

2-Nitrobenzyl bromide (15.31 mmol) was dissolved in THF (115 mL) and added dropwise to a stirring solution of requisite amino alcohol (61.2 mmol), DIPEA (61.2 mmol), and 38 mL of

isopropanol over 6 h and then left stirring overnight. Water (15 mL) and KOH (76.6 mmol) were then added and this mixture was heated at 60 °C for 24 h and monitored by thin layer chromatography. When the starting material had been consumed, 50 mL of water was added and the alcoholic solvent was removed under reduced pressure. This aqueous mixture was then extracted twice with dichloromethane. The combined organic extracts were washed with water and brine, dried over sodium sulfate, and concentrated. The crude mixture was purified by flash chromatography to afford the title compound. ²⁵⁻²⁷

4.4.5 General Procedure for conversion of 2*H*-indazoles into 1*H*-indazalones (5a-5f)

The precursor 2*H*-indazole (0.813 mmol) was dissolved in MeOH (4 mL) in a sealed microwave vial. H_2SO_4 (4.07 mmol) was added and heated at 100 °C overnight. This solution was then allowed to room temperature and neutralized with a saturated solution of NaHCO₃. This aqueous solution was extracted with EtOAc (3 X 25 mL) and the combined organic extracts were dried over anhydrous sodium sulfate and concentrated. This crude material was then purified by flash chromatography to afford the title compound.²⁸

4.4.6 General procedure for the synthesis of N^1, N^2 -disubstituted-1*H*-indazolones (6a-6f)

The requisite indazole (205 mg, 1.08 mmol) was added to a two-neck round bottom flask fitted with a water-cooled reflux condenser and an N₂ balloon, then dissolved in dry acetonitrile (10 mL). R²X (334 μ L, 4.32 mmol) was added and the solution was heated at reflux until TLC analysis showed consumption of the indazole. The acetonitrile was then removed under reduced pressure and the crude material was dissolved in ethyl acetate (30 mL). This solution was then poured into saturated sodium carbonate (20 mL) and the layers were separated. The organic extracts were then washed with water, brine, dried over sodium sulfate, and concentrated. This crude material was purified by flash chromatography to afford the title compound.²⁹

4.4.7 General procedure for the synthesis of thiazolo- and thiazolino-2*H*-indazoles (12a-12d)

2-Nitrobenzaldehyde or 6-nitropiperonal (1.1 eq) and requisite S-trityl protected 1°-aminothioalkane (1 eq) were dissolved in MeOH (0.4 M) in a 50 mL round-bottomed flask. The solution was stirred until TLC showed consumption of the starting 1°aminothioalkane. Sodium cyanoborohydride (2 eq) was added portionwise and this solution was stirred until TLC showed consumption of imine. The solution was concentrated and the resulting residue was redissolved in methylene chloride. The organic layer was washed twice with 1M HCl, dried over sodium sulfate and concentrated to ~15 mL. To this solution was added an equal volume of TFA, followed by triethylsilane (3 eq). The solution was stirred for 30 min. then concentrated. KOH (15 eq), MeOH (0.1 M) and 10% H₂O were added to the flask and the solution was heated in a 90 °C oil bath for 3-6 h. Upon reaction completion, the MeOH was evaporated and the remaining aqueous solution was partitioned with EtOAc. The aqueous layer was extracted twice with EtOAc and then the organic extracts were combined, washed with brine, dried over Na₂SO₄, and concentrated. Purification by silica gel chromatography provided products 12a-12d.³⁰

Acknowledgment

We thank the Tara K. Telford Fund for Cystic Fibrosis Research at the University of California-Davis and the National *Institutes of Health* (Grants HL092506, DK72517 and GM089153) for generous financial support of this work and gratefully acknowledge OpenEye for providing software. A.R. and S.O. contributed equally to this work.

Supplementary data

Supplementary data, including docking images, ¹H and ¹³C NMR spectra, and full experimental protocols can be found, in the online version, at ...

References

- 1. Arnhold, J.; Flemmig, J. Arch. Biochem. Biophys. 2010, 500, 92.
- 2. Klebanoff, S. J. J. Leukoc. Biol. 2005, 77, 598.
- Metzler, K. D.; Fuchs, T. A.; Nauseef, W. M.; Reumaux, D.; Roesler, J.; Schulze, I.; Wahn, V.; Papayannopoulos, V.; Zychlinsky, A. *Blood* 2011, 117, 953.
- Prokopowicz, Z.; Marcinkiewicz, J.; Katz, D. R.; Chain, B. M. Arch. Immunol. Ther. Exp. (Warsz) 2012, 60, 43.
- van der Veen, B. S.; de Winther, M. P. J.; Heeringa, P. Antioxid. Redox. Sign. 2009, 11, 2899.
- Rowe, S. M.; Miller, S.; Sorscher, E. J. New. Engl. J. Med. 2005, 352, 1992.
- Garner, H. P.; Phillips, J. R.; Herron, J. G.; Severson, S. J.; Milla, C. E.; Regelmann, W. E. J. Lab. Clin. Med. 2004, 144, 127.
- Thompson, E.; Brennan, S.; Senthilmohan, R.; Gangell, C. L.; Chapman, A. L.; Sly, P. D.; Kettle, A. J. Free Radical Bio. Med. 2010, 49, 1354.
- Van Der Vliet, A.; Nguyen, M. N.; Shigenaga, M. K.; Eiserich, J. P.; Marelich, G. P.; Cross, C. E. Am. J. Physiol. – Lung C. 2000, 279, 537.
- Regelmann, W. E.; Siefferman, C. M.; Herron, J. G.; Elliott, G. R.; Clawson, C. C.; Gray, B. H. *Pediatr. Pulm.* **1996**, *19*, 1.
- Van Der Vliet, A.; Eiserich, J. P.; Marelich, G. P.; Halliwell, B.; Cross, C. E. Advances in Pharmacology 1997, 38, 491.
- 12. Lucas, S.; Costa, E.; Guedes, R. C.; Moreira, R. *Med. Res. Rev.* 2013, *33*, E73.
- 13. Cantin, A. M.; White, T. B.; Cross, C. E.; Forman, H. J.; Sokol, R. J.; Borowitz, D. Free Radical Biol. Med. 2007, 42, 15.
- Kettle, A. J.; Chan, T.; Osberg, I.; Senthilmohan, R.; Chapman, A. L.; Mocatta, T. J.; Wagener, J. S. Am. J. Respir. Crit. Care Med. 2004, 170, 1317.
- Gorudko, I. V.; Grigorieva, D. V.; Shamova, E.V.; Kostevich, V. A.; Sokolov, A. V.; Mikhalchik, E. V.; Cherenkevich, S. N.; Arnhold, J.; Panasenko, O. M. *Free Radical Biol. Med.* **2014**, *68*, 326.
- 16. Huang, Y.; DiDonato, J. A.; Levison, B. S.; Schmitt, D.; Li, L.; Wu, Y.; Buffa, J.; Kim, T.; Gerstenecker, G. S.; Gu, X.; Kadiyala, C. S.; Wang, Z.; Culley, M. K.; Hazen, J. E.; DiDonato, A. J.; Fu, X.; Berisha, S. Z.; Peng, D.; Nguyen, T. T.; Liang, S.; Chuang, C.-C.; Cho, L.; Plow, E. F.; Fox, P. L.; Gogonea, V.; Tang, W. H. W.; Parks, J. S.; Fisher, E. A.; Smith, J. D.; Hazen, S. L. Nat. Med. **2013**, 20, 193.
- Reynolds, W. F.; Rhees, J.; Maciejewski, D.; Paladino, T.; Sieburg, H.; Maki, R. A.; Masliah, E. *Exp. Neurol.* **1999**, *155*, 31.
- Malle, E.; Furtmuller, P. G.; Sattler, W.; Obinger, C. Br. J. Pharmacol. 2007, 152, 838.
- Churg, A.; Marshall, C. V.; Sin, D. D.; Bolton, S.; Zhou, S.; Thain, K.; Cadogan, E. B.; Maltby, J.; Soars, M. G.; Mallinder, P. R.; Wright, J. L. Am. J. Respir. Crit. Care Med. 2012, 185, 34.
- Forbes, L. V.; Sjogren, T.; Auchere, F.; Jenkins, D. W.; Thong, B.; Laughton, D.; Hemsley, P.; Pairaudeau. G.; Turner, R.; Eriksson, H.; Unitt, J. F.; Kettle, A. J. J. Biol. Chem. 2013, 51, 36636.
- Tidén, A. K.; Sjögren T.; Svensson, M.; Bernlind, A.; Senthilmohan, R.; Auchère, F.; Norman, H.; Markgren, P. O.; Gustavsson, S.; Schmidt, S.; Lundquist, S.; Forbes, L. V.; Magon, N. J.; Paton, L. N.; Jameson, G. N.; Eriksson, H.; Kettle, A. J. J. Biol. Chem., 2011, 43, 37578.
- Soubhye, J.; Prevost, M.; Van Antwerpen, P.; Zouaoui Boudjeltia, K.; Rousseau, A.; Furtmuller, P. G.; Obinger, C.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J.; Gelbcke, M.; Dufrasne, F. O. *J. Med. Chem.* 2010, *53*, 8747.
- Mills, A. D.; Nazer, M. Z.; Haddadin, M. J.; Kurth, M. J., N,N-Bond-Forming Heterocyclization: J. Org. Chem. 2006, 71, 2687.
- Oakdale, J. S.; Solano, D. M.; Fettinger, J. C.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2009, 11, 2760.
- Butler, J. D.; Solano, D. M.; Robins, L. I.; Haddadin, M. J.; Kurth, M. J. J. Org. Chem. 2008, 73, 234.
- Donald, M. B.; Conrad, W. E.; Oakdale, J. S.; Butler, J. D.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2010, 12, 2524.

, North

- 27. Avila, B.; Solano, D. M.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2011, 13, 1060.
- Conrad, W. E.; Fukazawa, R.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2011, 13, 3138.
- Conrad, W. E.; Rodriguez, K. X.; Nguyen, H. H.; Fettinger, J. C.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2012, 14, 3870.
- Farber, K. M.; Haddadin, M. J.; Kurth, M. J. J. Org. Chem. 2014, 79, 6939.
- Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. J. Chem. Inf. Model. 2010, 50, 572.
- OpenEye Scientific Software, I, version 1.7.4 ed.; 2010, OpenEye: Santa Fe, NM, http://www.eyesopen.com. 2010.
- 33. Hawkins, P. C. D.; Nicholls, A. J. Chem. Inf. Model. 2012, 52, 2919.
- 34. Soubhye, J.; Aldib, I.; Elfving, B.; Gelbcke, M.; Furtmüller, P. G.; Podrecca, M.; Conotte, R.; Colet, J.-M.; Rousseau, A.; Reye, F.; Sarakbi, A.; Vanhaeverbeek, M.; Kauffmann, J.-M.; Obinger, C.; Nève, J.; Prévost, M.; Zouaoui Boudjeltia, K.; Dufrasne, F.; Van Antwerpen, P. J. Med. Chem. 2013, 56, 3943.
- Sliskovic, I.; Abdulhamid, I.; Sharma, M.; Abu-Soud, H. M. Free Radical Biol. Med. 2009, 47, 1005.
- 36. Van Antwerpen, P.; Prévost, M.; Zouaoui-Boudjeltia, K.; Babar, S.; Legssyer, I.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Nève, J.; Dufrasne, F. *Bioorgan. Med. Chem.* **2008**, *16*, 1702.
- Veber, D. F.; Johnson, S. R.; Cheng, H.; Smith, B. R.; Ward, K. W.; Kopple, K. D. J. Med. Chem. 2002, 45, 2615
- 38. Hou, T. J.; Xu, X. J. J. Chem. Inf. Comput. Sci. 2003, 43, 2137.
- Choi, D. K.; Pennathur, S.; Perier, C.; Tieu, K.; Teismann, P.; Wu, D. C.; Jackson-Lewis, V.; Vila, M.; Vonsattel, J.; Heinecke, J. W.; Prezedborski, S. J. Neurosci. 2005, 25, 6594.
- Kajer, T. B.; Fairfull-Smith, K. E.; Yamasaki, T.; Yamada, K.; Fu, S.; Bottle, S. E.; Hawkins, C. L.; Davies, M. J. *Free Radical Biol. Med.* 2014, 70, 96.
- van der Does, A. M.; Hensbergen, P. J.; Bogaards, S. J.; Cansoy, M.; Deelder, A. M.; van Leeuwen, H. C.; Drijfhout, J. W.; van Dissel, J. T.; Nibbering, P. H. J. Immunol. 2012, 10, 5012.
- 42. Frisch, M.J. *Gaussian 09, Revision B.01* Gaussian, Inc. Wallingford, CT, **2010** (for full reference, see *Supporting Information*).
- Dypbukt, J. M.; Bishop, C.; Brooks, W. M.; Thong, B.; Eriksson, H.; Kettle, A. J. Free Radical Biol. Med. 2005, 39, 1468.





Table 1. IC₅₀ values of 3-alkoxy-2*H*-indazoles assessed with a Taurine chlorination assay (154 mM NaCl, 30 μ M H₂O₂, and 2 nM MPO). All IC₅₀ values are expressed in nM as a mean of \geq 3 trials +/- standard deviation.





Table 2: IC₅₀ values of 1*H*-indazolones assessed with a Taurine chlorination assay (154 mM NaCl, 30 μ M H₂O₂, and 2 nM MPO). All IC₅₀ values are expressed in nM as a mean of \geq 3 trials +/- standard deviation.





Table 3. IC₅₀ values of constrained 2*H*-indazole analogues assessed with a Taurine chlorination assay (154 mM NaCl, 30 μ M H₂O₂, and 2 nM MPO). All IC₅₀ vales are expressed in nM as a mean of \geq 3 trials +/- standard deviation.

MA G

		Molecular						
Cmpd	HBD	HBA	XLogP	2D PSA	Weight	Score	IC50 (nM)	
12b	0	3	1.72	36.28	220.3	-44.74	87	
12a	0	1	1.99	17.82	176.2	-46.65	94	
12d	0	3	2.21	36.28	234.3	-41.23	140	
12c	0	1	2.48	17.82	190.3	-43.61	213	
9c	0	2	1.75	27.05	174.2	-38.09	359	
9e	0	4	1.48	45.51	218.2	-35.45	403	
5a	1	2	2.03	37.79	176.2	-39.94	660	
4 a	0	2	2.76	27.05	190.2	-47.20	704	
4d	0	4	2.49	45.51	234.3	-63.55	711	
4b	0	2	3.16	27.05	204.3	-50.03	722	
5b	1	2	2.48	37.79	190.2	-48.13	792	
4f	0	2	3.61	27.05	218.3	-53.95	807	
9a	0	2	1.79	27.05	174.2	-39.72	900	
4 e	0	2	3.21	27.05	204.3	-50.64	910	

Table 4. Drug like properties of select compounds (mean IC_{50} values are shown); see *Supporting Information* for a complete tabulation of results.

- MA